Enterprise Value
29.03M
Cash
97.31M
Avg Qtr Burn
-18.82M
Short % of Float
5.67%
Insider Ownership
7.72%
Institutional Own.
64.28%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vidofludimus calcium (IMU-838) Details Multiple sclerosis, Autoimmune disease | Phase 3 Data readout | |
Vidofludimus calcium (IMU-838) Details Bowel disorder, Inflammatory bowel disease, Ulcerative colitis | Phase 2b Update | |
IMU-856 Details Celiac disease | Phase 2b Initiation | |
Vidofludimus calcium (IMU-838) Details Multiple sclerosis, Autoimmune disease | Phase 2 Data readout | |
Vidofludimus calcium (IMU-838) Details COVID-19, Infectious disease | Phase 2 Update | |
Vidofludimus calcium (IMU-838) Details Primary sclerosing cholangitis, Bile duct disease, Liver disease | Failed Discontinued | |
Izumerogant (IMU-935) Details Psoriasis | Failed Discontinued |